Welcome to our dedicated page for INTUITIVE SURGICAL SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical director Keith R. Leonard reported a change in his holdings of Intuitive Surgical, Inc. common stock. On 01/29/2026, 369 shares of common stock were transferred at a price of $0.0 per share, coded as transaction type "J" for “other.”
The footnote explains this was a transfer of shares pursuant to a divorce decree, indicating a personal, court-directed reallocation rather than an open‑market trade. After this transaction, Leonard beneficially owns 370 shares of Intuitive Surgical common stock in direct form.
Intuitive Surgical executive Mark Brosius reported new performance-based equity awards. On January 28, 2026, he was credited with 2,702 performance stock units tied to a grant dated February 26, 2024 and 5,585 performance stock units tied to a grant dated February 28, 2023.
The company’s compensation committee determined the performance criteria for both awards had been achieved. The 2024-related units are scheduled to vest on February 26, 2027, and the 2023-related units on February 28, 2026, in each case requiring Brosius to remain in continuous service until those vesting dates.
Intuitive Surgical executive Gary Loeb reported performance-based equity awards. On January 28, 2026, he acquired 2,543 performance stock units tied to a February 26, 2024 grant and 2,098 performance stock units tied to a February 28, 2023 grant, each at a stated price of 0.0 per unit.
The company’s compensation committee determined that required performance goals were achieved. The 2023-related units are scheduled to vest on February 28, 2026, and the 2024-related units on February 26, 2027, in each case contingent on Loeb’s continued service with Intuitive Surgical.
Intuitive Surgical’s Chief Executive Officer and director David J. Rosa reported grants of performance stock units that have now been earned based on previously set goals. On January 28, 2026, he acquired 6,360 PSUs from a February 26, 2024 grant, 9,575 PSUs from a February 28, 2023 grant, and 6,034 PSUs from a June 12, 2023 grant.
The compensation committee confirmed that the performance criteria for each grant were achieved. These PSUs convert into common stock if Rosa remains in continuous service through the vesting dates: February 26, 2027 for the 2024 grant and February 28, 2026 for the 2023 and June 2023 grants.
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported option and stock transactions plus performance stock units. On January 29, 2026, she exercised 126 non-qualified stock options at $208.9 per share and sold 126 common shares at $520.02 per share under a Rule 10b5-1 trading plan that expires July 29, 2026.
Following these trades, she reported no directly held common stock and 353 common shares held indirectly through a trust. Separately, on January 28, 2026, 5,585 performance stock units granted on February 28, 2023 were reported after the company confirmed performance goals were achieved; these PSUs are scheduled to vest on February 28, 2026, subject to continued service.
Intuitive Surgical director Gary S. Guthart reported new performance-based equity awards. On January 28, 2026, he acquired 8,267 performance stock units (PSUs) tied to a February 26, 2024 grant and 17,556 PSUs tied to a February 28, 2023 grant, each at an exercise price of $0.0.
The Compensation Committee determined that the performance goals for both PSU grants were achieved. The 2024 grant PSUs are scheduled to vest on February 26, 2027, and the 2023 grant PSUs are scheduled to vest on February 28, 2026, in each case if Guthart remains in continuous service to Intuitive Surgical through those dates.
Intuitive Surgical executive Henry L. Charlton, EVP & Chief Commercial and Marketing, reported the achievement of performance conditions for two performance stock unit (PSU) awards. One award covers 2,861 PSUs granted on February 26, 2024, vesting on February 26, 2027, subject to continued service. The second covers 7,182 PSUs granted on February 28, 2023, vesting on February 28, 2026, also conditioned on ongoing employment.
Intuitive Surgical executive Jamie Samath, EVP & CFO & Enterprise Technol, reported performance stock unit awards tied to prior grants. On January 28, 2026, 3,180 PSUs from a February 26, 2024 grant and 7,182 PSUs from a February 28, 2023 grant were credited after performance criteria were achieved.
The 2024 grant PSUs vest on February 26, 2027, and the 2023 grant PSUs vest on February 28, 2026, in each case subject to Samath’s continuous service to Intuitive Surgical through the respective third-anniversary vesting dates.
ISRG security holder Curet McAdams filed a Rule 144 notice to sell 126 shares of common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $65,522.52. The shares were acquired on 01/29/2026 via a stock option exercise paid in cash.
The notice states 354,496,073 shares of common stock outstanding and an approximate sale date of 01/29/2026. Over the prior three months, Curet McAdams sold additional common shares in several transactions, each with disclosed share amounts and gross proceeds.
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported option exercises and stock sales in Intuitive Surgical, Inc. common stock. On January 27, 2026, she exercised options for 105 shares at $229.39 and 125 shares at $208.90, then sold 105 shares and 125 shares at $532.61 per share.
The filing notes these trades occurred under a Rule 10b5-1 trading plan that expires on July 29, 2026. After these transactions, the report shows 251 and 1,362 non-qualified stock options remaining directly held and 353 common shares held indirectly by a trust.